The treatment of inflammatory bowel disease with monoclonal antibodies in Asia

Chen, Yu; Zhang, Guolin; Yang, Yuewen; Zhang, Shuangshuang; Jiang, Haozheng; Tian, Kui; Arenbaoligao,; Chen, Dapeng

doi:10.1016/j.biopha.2022.114081

Cited by 10 publications

(13 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, application of the standard assays is significantly limited due to risk of trauma and invasiveness, especially in case of severe course and aggravation stages (Şimşek et al, 2016;Stepanov et al, 2021). Currently, there are non-invasive markers that are already being used to improve the diagnosis of inflammatory bowel disease, but they do not always answer the questions of prognosis, evaluation of treatment efficacy, and therefore assays and use of new non-invasive biomarkers would improve both diagnostic and prognostic possibilities (Fleming et al, 2022;Chen et al, 2023). Such a biomarker could be IgG4.…”

Section: Discussionmentioning

confidence: 99%

“…Inflammatory bowel disease is a chronic disease of the gastrointestinal tract occurring in two main forms: ulcerative colitis and Crohn's disease. Though the etiology and pathogenesis of ulcerative colitis and Crohn's disease are still unknown, an important role in both cases is played by immunologic mechanisms (Uo et al, 2013;Şimşek et al, 2016;Chen et al, 2023). Oftentimes, it is hard to perform differentiation diagnosis between ulcerative colitis and Crohn's disease in patients with inflammatory bowel disease, manifestations of which are limited by the colon and are not characterized by typical endoscopic or histological data.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of inflammatory bowel disease according to human IgG4 and possibilities of evaluating efficacy of the therapy

Stepanov

Тарасова

Stoykevich

et al. 2022

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

Taking into account the progress of understanding diagnosis, course prognosis, evaluation of effectiveness of therapy of inflammatory bowel disease and also differentiation diagnosis between its main forms – ulcerative colitis and Crohn’s disease, the search for efficient non-invasive markers for solving those issues is extremely relevant. The patients were divided into groups depending on nosology and severity of the course of the disease. All the patients had undergone endoscopic study for diagnosis verification and biopsy samples were taken for further detection of tissue IgG4 using the immunohistochemical method. Also, we determined concentration of serum IgG4. Increase in IgG4content in blood serum was determined in 54.0% of the cases of inflammatory bowel disease. Concentration of IgG4 in patients suffering ulcerative colitis was higher (by 2.31 and 2.46 times) compared with its level in the control group and patients with Crohn’s disease, respectively. We found relationships between the concentration of serum IgG4 and the activity of the disease. In patients with ulcerative colitis, increased tissue IgG4 was found more often than in patients with Crohn’s disease (by 2.77 times, Р < 0.05). We determined the relationship between tissue IgG4 and histological activity. Simultaneous increase in serum IgG4 and presence of tissue IgG4 during ulcerative colitis were more frequent than during Crohn’s disease (by 2.66 times). In all examined groups of patients, we determined decrease in serum IgG4 content (by 1.66 times) after treatment. Concentration of serum IgG4 and positive tissue IgG4 in ulcerative colitis patients exceeded such in Crohn’s disease patients, which may be used for differentiation diagnosis between those disease types. We determined dependence of IgG4 concentration on severity and duration of the disease, which could be used as a prognostic marker. Decrease in IgG4 content in blood serum against the background of the therapy shows that this indicator could be used as a marker of treatment efficacy. Perspectives of further studies are as follows: parameters of concentration of serum IgG4 and presence of tissue IgG4 could be used as diagnostic and prognostic biomarkers and be introduced to practice for differentiation diagnosis between ulcerative colitis and Crohn’s disease, and could be used as prognostic marker of severity of the disease and therapy efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnosis of inflammatory bowel disease according to human IgG4 and possibilities of evaluating efficacy of the therapy

Stepanov

Тарасова

Stoykevich

et al. 2022

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

“…As for laboratory tests, patients should be monitored for anemia, hypoalbuminemia, and elevated C-reactive protein (CRP). Elevated fecal calprotectin is a sensitive (but not specific) indicator of intestinal inflammation in IBD [182].…”

Section: Clinical Aspectsmentioning

confidence: 94%

Exploring the Impact of Cyanidin-3-Glucoside on Inflammatory Bowel Diseases: Investigating New Mechanisms for Emerging Interventions

Frountzas,

Karanikki,

Toutouza

et al. 2023

IJMS

View full text Add to dashboard Cite

Cyanidin-3-O-glucoside (C3G), the most widely distributed anthocyanin (ACN) in edible fruits, has been proposed for several bioactivities, including anti-inflammatory, neuro-protective, antimicrobial, anti-viral, anti-thrombotic and epigenetic actions. However, habitual intake of ACNs and C3G may vary widely among populations, regions, and seasons, among individuals with different education and financial status. The main point of C3G absorption occurs in the small and large bowel. Therefore, it has been supposed that the treating properties of C3G might affect inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn’s disease (CD). IBDs develop through complex inflammatory pathways and sometimes may be resistant to conventional treatment strategies. C3G presents antioxidative, anti-inflammatory, cytoprotective, and antimicrobial effects useful for IBD management. In particular, different studies have demonstrated that C3G inhibits NF-κB pathway activation. In addition, C3G activates the Nrf2 pathway. On the other hand, it modulates the expression of antioxidant enzymes and cytoprotective proteins, such as NAD(P)H, superoxide dismutase, heme-oxygenase (HO-1), thioredoxin, quinone reductase-oxide 1 (NQO1), catalase, glutathione S-transferase and glutathione peroxidase. Interferon I and II pathways are downregulated by C3G inhibiting interferon-mediating inflammatory cascades. Moreover, C3G reduces reactive species and pro-inflammatory cytokines, such as C reactive protein, interferon-γ, tumor necrosis factor-α, interleukin (IL)-5, IL-9, IL-10, IL-12p70, and IL-17A in UC and CD patients. Finally, C3G modulates gut microbiota by inducing an increase in beneficial gut bacteria and increasing microbial abundances, thus mitigating dysbiosis. Thus, C3G presents activities that may have potential therapeutic and protective actions against IBD. Still, in the future, clinical trials should be designed to investigate the bioavailability of C3G in IBD patients and the proper therapeutic doses through different sources, aiming to the standardization of the exact clinical outcome and efficacy of C3G.

show abstract

“…Inflammatory bowel disease (IBD) is a serious gastrointestinal disorder that typically presents with symptoms, such as diarrhea, abdominal discomfort, bloody stools and weight loss. Persistent inflammation may elevate the likelihood of developing severe conditions, including colorectal cancer (Chen et al 2023 ). The main therapeutic agents for IBD currently include chemotherapeutic agents (aminosalicylates) and protein drugs (infliximab and adalimumab).…”

Section: Introductionmentioning

confidence: 99%

“…The main therapeutic agents for IBD currently include chemotherapeutic agents (aminosalicylates) and protein drugs (infliximab and adalimumab). These drugs are typically administered systemically via intravenous injection to treat IBD (Chen et al 2023 ). It is worth noting that intravenous administration of protein drugs is prone to adverse reactions, with a higher incidence of allergic reactions than that oral administration (Hanauer et al 2002 ; Lichtenstein et al 2006 ).…”

Section: Introductionmentioning

confidence: 99%

Dual engineered bacteria improve inflammatory bowel disease in mice

Wu,

Zou,

Zhou

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Currently, there are many different therapies available for inflammatory bowel disease (IBD), including engineered live bacterial therapeutics. However, most of these studies focus on producing a single therapeutic drug using individual bacteria, which may cause inefficacy. The use of dual drugs can enhance therapeutic effects. However, expressing multiple therapeutic drugs in one bacterial chassis increases the burden on the bacterium and hinders good secretion and expression. Therefore, a dual-bacterial, dual-drug expression system allows for the introduction of two probiotic chassis and enhances both therapeutic and probiotic effects. In this study, we constructed a dual bacterial system to simultaneously neutralize pro-inflammatory factors and enhance the anti-inflammatory pathway. These bacteria for therapy consist of Escherichia coli Nissle 1917 that expressed and secreted anti-TNF-α nanobody and IL-10, respectively. The oral administration of genetically engineered bacteria led to a decrease in inflammatory cell infiltration in colon and a reduction in the levels of pro-inflammatory cytokines. Additionally, the administration of engineered bacteria did not markedly aggravate gut fibrosis and had a moderating effect on intestinal microbes. This system proposes a dual-engineered bacterial drug combination treatment therapy for inflammatory bowel disease, which provides a new approach to intervene and treat IBD. Key points • The paper discusses the effects of using dual engineered bacteria on IBD • Prospects of engineered bacteria in the clinical treatment of IBD Graphical Abstract

show abstract

The treatment of inflammatory bowel disease with monoclonal antibodies in Asia

Cited by 10 publications

References 91 publications

Diagnosis of inflammatory bowel disease according to human IgG4 and possibilities of evaluating efficacy of the therapy

Diagnosis of inflammatory bowel disease according to human IgG4 and possibilities of evaluating efficacy of the therapy

Exploring the Impact of Cyanidin-3-Glucoside on Inflammatory Bowel Diseases: Investigating New Mechanisms for Emerging Interventions

Dual engineered bacteria improve inflammatory bowel disease in mice

Contact Info

Product

Resources

About